Mumbai: Pharma major Lupin announced the launch of its Clonidine Hydrochloride extended-release tablets for the treatment of attention deficit hyperactivity disorder (ADHD).
The Clonidine Hydrochloride extended-release tablets 0.1mg have received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Clonidine Hydrochloride ER tablets are the generic equivalent of Concordia International Corp’s Kapvay® tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Kapvay tablets had annual sales of approximately USD 66 million in the US.